Figure 1From: Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus – results from an exploratory study Mean change from baseline in retinal blood flow (RBF) during glimepiride and vildagliptin treatment after 12 and 24 weeks of treatment (□ = glimepiride; ■ = vildagliptin; mean ± SEM; * = p < 0.05 vs. baseline). Back to article page